Cargando…
Rosiglitazone may reduce non-melanoma skin cancer risk in Taiwanese
BACKGROUND: Whether rosiglitazone may affect the risk of non-melanoma skin cancer (NMSC) has not been investigated. METHODS: The reimbursement databases of all Taiwanese diabetic patients from 1996 to 2009 were retrieved from the National Health Insurance. An entry date was set at 1 January 2006 and...
Autor principal: | Tseng, Chin-Hsiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4325941/ https://www.ncbi.nlm.nih.gov/pubmed/25655946 http://dx.doi.org/10.1186/s12885-015-1057-8 |
Ejemplares similares
-
Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus
por: Tseng, Chin-Hsiao
Publicado: (2016) -
Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients
por: Tseng, Chin-Hsiao
Publicado: (2023) -
Metformin Reduces Thyroid Cancer Risk in Taiwanese Patients with Type 2 Diabetes
por: Tseng, Chin-Hsiao
Publicado: (2014) -
Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients
por: Tseng, Chin-Hsiao
Publicado: (2023) -
Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients
por: Tseng, Chin-Hsiao
Publicado: (2019)